{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:48:49Z","timestamp":1767116929197,"version":"3.37.3"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nDespite the fact that direct oral anticoagulants (DOACs) are favoured over warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), physicians need to maintain competence in using and monitoring warfarin since many patients have contraindications or other barriers to using DOACs. Unlike DOACs, warfarin therapy requires regular blood testing to ensure that it is within a target range to ensure efficacy and safety. There is limited real-world data on the adequacy of warfarin control and the cost and burden of monitoring warfarin therapy in Canadian NVAF patients.<\/jats:p>\n<\/jats:sec>\n\nObjectives<\/jats:title>\nIn a large cohort of Canadian patients with NVAF on warfarin we assessed time in therapeutic range (TTR), determinants of TTR, process of care, direct costs, health related quality of life and loss of work time and productivity related to warfarin therapy.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nFive hundred and fifty one patients with NVAF, either newly initiated or stable on warfarin were prospectively enrolled across 9 Canadian provinces from primary care practices and anticoagulant clinics. Participating physicians provided baseline demographic and medical information. Patients completed diaries for 48 weeks, capturing information about International Normalized Ratio (INR) test results, test locations, process of INR monitoring, direct costs of travel, health-related quality of life and work productivity measures. TTR was estimated using linear interpolation of INR results and linear regression used to investigate associations between TTR and factors (defined a priori).<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nFour hundred and eighty (87.1%) patients had complete follow-up with an overall TTR of 74.4% based on 7,175 physician-reported INR values from 501 patients. 88% of this cohort were monitored through routine medical care (RMC). The average number of INRs per patient during the 48-week period was 14.1 (standard deviation (SD) = 8.3) tests with a mean duration of 23.8 (SD = 11.1) days between tests. We did not find a relationship between TTR and age, sex, presence of major comorbidities, patient\u2019s province of residence or rural vs. urban residence. 12% of patients monitored through anticoagulant clinics had significantly better TTR than patients monitored through RMC (82% vs. 74%; 95% confidence interval: -13.8, -1.2; p = 0.02). Health related quality of life utility values were high and remained consistent throughout the study. The majority of patients reported no impact on either work productivity or impairment of regular activities due to being on long-term warfarin treatment.<\/jats:p>\n<\/jats:sec>\n\nConclusions<\/jats:title>\nWe showed excellent overall TTR in an observed Canadian cohort, with monitoring through a dedicated anticoagulant clinic being associated with a statistically and clinically significant improvement in TTR. The burden of warfarin therapy on patients\u2019 health related quality of life or daily work and activities was low.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0284425","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T17:27:15Z","timestamp":1681838835000},"page":"e0284425","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study"],"prefix":"10.1371","volume":"18","author":[{"given":"Rita","family":"Selby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Kaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith","family":"Sealey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Parpia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-0446","authenticated-orcid":true,"given":"Brian","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jin","family":"Seung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"2 Suppl","key":"pone.0284425.ref001","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"GH Guyatt","year":"2012","journal-title":"Chest."},{"issue":"5","key":"pone.0284425.ref002","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.","volume":"154","author":"GYH Lip","year":"2018","journal-title":"Chest"},{"issue":"2","key":"pone.0284425.ref003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest."},{"issue":"3","key":"pone.0284425.ref004","doi-asserted-by":"crossref","first-page":"e13070","DOI":"10.1111\/ijcp.13070","article-title":"Epidemiology of atrial fibrillation.","volume":"72","author":"H Zulkifly","year":"2018","journal-title":"Int J Clin Pract"},{"issue":"20","key":"pone.0284425.ref005","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"MD Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0284425.ref006","first-page":"Cd001927","article-title":"Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks","author":"MI Aguilar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0284425.ref007","first-page":"Cd006186","article-title":"Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks","author":"MI Aguilar","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0284425.ref008","first-page":"Cd008980","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.","volume":"3","author":"KM Bruins Slot","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"2 Suppl","key":"pone.0284425.ref009","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"A Holbrook","year":"2012","journal-title":"Chest."},{"issue":"11","key":"pone.0284425.ref010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"EM Hylek","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0284425.ref011","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"EM Hylek","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0284425.ref012","first-page":"1087","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"110","author":"R De Caterina","year":"2013","journal-title":"Thrombosis and haemostasis"},{"issue":"5","key":"pone.0284425.ref013","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"AM Gallagher","year":"2011","journal-title":"Thrombosis and haemostasis"},{"issue":"6","key":"pone.0284425.ref014","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"P Gallego","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"pone.0284425.ref015","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and metaregression.","volume":"129","author":"C van Walraven","year":"2006","journal-title":"Chest"},{"issue":"5","key":"pone.0284425.ref016","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group.","volume":"33","author":"R Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"2","key":"pone.0284425.ref017","doi-asserted-by":"crossref","first-page":"e31115","DOI":"10.1371\/journal.pone.0031115","article-title":"Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.","volume":"7","author":"N Bansback","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"pone.0284425.ref018","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"FR Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"12","key":"pone.0284425.ref019","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0284425.ref020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0284425.ref021","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0284425.ref022","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0284425.ref023","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"L Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"pone.0284425.ref024","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"DE Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"9745","key":"pone.0284425.ref025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"L Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"pone.0284425.ref026","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.amjcard.2016.08.047","article-title":"Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT).","volume":"118","author":"GY Lip","year":"2016","journal-title":"Am J Cardiol."},{"issue":"1","key":"pone.0284425.ref027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry","volume":"170","author":"SD Pokorney","year":"2015","journal-title":"Am Heart J"},{"issue":"11","key":"pone.0284425.ref028","doi-asserted-by":"crossref","first-page":"e0188482","DOI":"10.1371\/journal.pone.0188482","article-title":"The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.","volume":"12","author":"AS Vestergaard","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"pone.0284425.ref029","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"CT January","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"pone.0284425.ref030","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"S Zuily","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"pone.0284425.ref031","first-page":"293","article-title":"Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial.","volume":"169","author":"SJ Wilson","year":"2003","journal-title":"CMAJ"},{"issue":"5","key":"pone.0284425.ref032","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1062860607303003","article-title":"Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care","volume":"22","author":"J Ansell","year":"2007","journal-title":"Am J Med Qual"},{"key":"pone.0284425.ref033","first-page":"181","article-title":"Short report: managing anticoagulation. Comparison of results at three primary care centres","volume":"49","author":"RE Upshur","year":"2003","journal-title":"Can Fam Physician"},{"issue":"6","key":"pone.0284425.ref034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0828-282X(07)70784-5","article-title":"The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study","volume":"23","author":"R Parkash","year":"2007","journal-title":"Can J Cardiol"},{"issue":"10","key":"pone.0284425.ref035","first-page":"e425","article-title":"Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice.","volume":"63","author":"D Gateman","year":"2017","journal-title":"Can Fam Physician"},{"issue":"1","key":"pone.0284425.ref036","doi-asserted-by":"crossref","first-page":"e016980","DOI":"10.1136\/bmjopen-2017-016980","article-title":"Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada.","volume":"8","author":"FA McAlister","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0284425.ref037","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","article-title":"Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).","volume":"23","author":"J Ansell","year":"2007","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"pone.0284425.ref038","first-page":"244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.","volume":"15","author":"WL Baker","year":"2009","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"pone.0284425.ref039","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1503\/cmaj.170317","article-title":"Age- and sex-specific Canadian utility norms, based on the 2013\u20132014 Canadian Community Health Survey.","volume":"190","author":"JR Guertin","year":"2018","journal-title":"CMAJ"},{"issue":"10","key":"pone.0284425.ref040","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1001\/archinte.1991.00400100032005","article-title":"The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","volume":"151","author":"TR Lancaster","year":"1991","journal-title":"Arch Intern Med"},{"issue":"10","key":"pone.0284425.ref041","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/europace\/eus102","article-title":"A cross-sectional study of quality of life in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation Treatment of the Aged study.","volume":"14","author":"AK Roalfe","year":"2012","journal-title":"Europace."},{"issue":"6","key":"pone.0284425.ref042","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1046\/j.1365-2389.2003.51280.x","article-title":"The effect of stability of oral anticoagulant therapy upon patient-perceived health status and quality of life.","volume":"51","author":"F Jaffary","year":"2003","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"pone.0284425.ref043","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ageing\/afl062","article-title":"The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation.","volume":"36","author":"AK Das","year":"2007","journal-title":"Age Ageing"},{"issue":"6","key":"pone.0284425.ref044","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/ageing\/afp158","article-title":"Quality of life of elderly people on warfarin for atrial fibrillation.","volume":"38","author":"AK Das","year":"2009","journal-title":"Age Ageing."},{"issue":"3","key":"pone.0284425.ref045","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.ijcard.2013.03.059","article-title":"Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.","volume":"168","author":"BU Monz","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T17:27:50Z","timestamp":1681838870000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284425"}},"subtitle":[],"editor":[{"given":"Redoy","family":"Ranjan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284425","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}